Bispecific nanobodies as a therapeutic for alzheimer's disease
AssigneeArizona Board of Regents, A Body Corporate of the State of Arizona Acting for and On Behalf of Arizona State University
InventorsMichael Sierks, Shanta Boddapati, Srinath Kasturirangan
Life of this patent
Estimating the term…
Abstract
The present invention provides for the treatment of Alzheimer's disease. More specifically, a recombinant bispecific antibody fragment that simultaneously blocks beta-secretase activity while also promoting alpha-secretase activity, comprising a first portion and a second portion, wherein the first portion blocks beta secretase activity and the second portion promotes alpha-secretase activity.
Claims18
A recombinant bispecific antibody, comprising a first portion and a second portion, wherein the first portion has an amino acid sequence selected from the group consisting of SEQ ID NO:
- 2 and SEQ ID NO:
- 3, and the second portion has an amino acid sequence selected from the group consisting of SEQ ID NO:
- 4 and SEQ ID NO:
- 5.
A recombinant bispecific antibody that has the amino acid sequence of SEQ ID NO:
- 1.
A method of dissolving a plaque comprising oligomers of Aβ comprising contacting said plaque with a recombinant bispecific antibody selected from:
- (a) a recombinant bispecific antibody that has the amino acid sequence of SEQ ID NO:
- 1;
- or
- (b) a recombinant bispecific antibody comprising a first portion and a second portion, wherein the first portion has an amino acid sequence selected from the group consisting of SEQ ID NO:
- 2 and SEQ ID NO:
- 3, and the second portion has an amino acid sequence selected from the group consisting of SEQ ID NO:
- 4 and SEQ ID NO:
- 5.
Dependencies are inferred from the claim text.